PSNResearch

PSNResearch

Barcelona, Spain· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Founded in 2015, PSNResearch is a private, revenue-generating clinical research organization (CRO) and services provider headquartered in Barcelona. The company provides comprehensive clinical development services with a strong focus on complex areas like advanced therapies (ATMPs), orphan drugs, neurology, and immuno-oncology. It operates by building unique partnerships for senior-level collaboration, guiding sponsors through regulatory processes, and managing trials from first-in-human to post-marketing. While not developing its own therapeutics, PSNResearch's model is built on deep therapeutic and regulatory expertise to de-risk and accelerate client programs.

Neurology and Neuro-Muscular DisordersRare DiseaseImmuno-OncologyGastroenterologyHematology/OncologyRheumatology

Technology Platform

Integrated clinical development services platform with expertise in regulatory strategy (EMA/FDA/CTIS), clinical trial management, biometrics/big data, and specialized support for Advanced Therapies (ATMPs) and orphan drugs. No proprietary therapeutic technology.

Opportunities

High growth in Advanced Therapy Medicinal Products (ATMPs) and orphan drug development creates strong demand for specialized CRO services.
Increasing regulatory complexity in the EU (e.g., CTIS) and globally drives biopharma outsourcing.
The trend towards virtual and agile biotech companies favors flexible, expert partners like PSNResearch.

Risk Factors

Intense competition from large global CROs and other niche providers.
Revenue dependency on securing and retaining client projects in a cyclical R&D environment.
Operational and reputational risk tied to the success of client trials.
High reliance on key senior personnel.

Competitive Landscape

PSNResearch competes in the fragmented global CRO market. It differentiates itself from large players (e.g., IQVIA, ICON) by offering senior-level, hands-on partnership and deep niche expertise in advanced therapies and complex trials. It faces competition from other specialized, mid-sized CROs focusing on similar therapeutic areas and service models in Europe.